Centre hospitalier

Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation Award

Retrieved on: 
Freitag, November 24, 2023
Senior, Partnership, Food, Treatment, Risk, Drug development, Breast cancer, Docetaxel, Drug discovery, FDA, Colorectal cancer, Centre hospitalier, American Cancer Society, Recurrence, Biochemistry, Innovation, Cancer, UQAM, TSX, Patient, Triple-negative breast cancer, Development, Fast Track, Pharmaceutical industry

MONTREAL, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of the 2023 Industrial Research Sectoral Group (RSRI) Innovation Award from the CQDM (formerly known as the Québec Consortium for Drug Discovery) and the Association for the Development of Research and Innovation of Québec (ADRIQ).

Key Points: 
  • MONTREAL, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of the 2023 Industrial Research Sectoral Group (RSRI) Innovation Award from the CQDM (formerly known as the Québec Consortium for Drug Discovery) and the Association for the Development of Research and Innovation of Québec (ADRIQ).
  • The award-winning research was funded by Theratechnologies, the Canadian Cancer Society, and the CQDM.
  • Theratechnologies and Prof. Annabi received the award last night (November 23) at the 2023 ADRIQ Innovation Awards Gala, at the Palais des Congrès de Montréal.
  • “With this innovative therapy currently in clinical trials, Theratechnologies is now in an excellent position to help make a difference for people living with advanced cancers.”

OSE Immunotherapeutics Announces First Clinical Results for BI 770371, a Novel Anti-SIRPα Monoclonal Antibody

Retrieved on: 
Montag, Oktober 23, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, OSE, MTD, HCC, Mnemos EP, ESMO, ISIN, Human, European Society for Medical Oncology, CD47, HNSCC, Hackensack Meridian Health, Boehringer Ingelheim, Centre hospitalier, Clinical trial, Immunoglobulin G, Partnership, Oncology, Tumor microenvironment, Hackensack University Medical Center, Cancer, Hepatocellular carcinoma, CHUM, Patient, Mab, Myelocyte, Vaccine, Fine chemical, Pharmaceutical industry, QC

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that first Phase 1 results for BI 770371, a novel anti-SIRPα monoclonal antibody evaluated in advanced solid tumors, have been presented, at the European Society for Medical Oncology conference , held in Madrid, Spain (October 20 – 24, 2023).

Key Points: 
  • OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that first Phase 1 results for BI 770371, a novel anti-SIRPα monoclonal antibody evaluated in advanced solid tumors, have been presented, at the European Society for Medical Oncology conference , held in Madrid, Spain (October 20 – 24, 2023).
  • BI 770371 is an IgG1 mAb that recognizes both the V1 and V2 variants of SIRPα.
  • We are very pleased to potentially make our selective SIRPα inhibitor technology available to more patients through this strategic collaboration.
  • The first clinical results of BI 770371 presented at ESMO 2023 conference (Madrid, Abstract #697P ) showed that adverse events were manageable during the on-treatment period, Maximal Tolerated Dose (MTD) has not been reached.

Domain Therapeutics announces nomination of first-in-class PAR2 NAM candidate, DT-9045, to unlock new cancer treatment possibilities

Retrieved on: 
Montag, Juni 5, 2023
Allosteric regulation, Failure, G protein-coupled receptor, CHUM, Centre hospitalier, Cancer, PAR2, GABAA receptor negative allosteric modulator, Research, CAF, NAM, Immunotherapy, Fibrosis, GPCR, Patient, Neoplasm, EP4, Therapy, Immunosuppression, Gq alpha subunit, Pharmaceutical industry, Vaccine

Through this precision research strategy, backed by two decades of deep-expertise in understanding GPCRs, the Company has developed a novel series of potent and selective PAR2 NAMs.

Key Points: 
  • Through this precision research strategy, backed by two decades of deep-expertise in understanding GPCRs, the Company has developed a novel series of potent and selective PAR2 NAMs.
  • PAR2 is a novel therapeutic target in oncology and immuno-oncology, involved in several processes such as tumor proliferation, resistance to immunotherapy and fibrosis.
  • Domain nominated DT-9045 as a first-in-class PAR2 NAM clinical candidate based on its added-value, unique properties and greater therapeutic potential in comparison to biologics targeting PAR2 currently in the clinic by several competitors.
  • Dr. Pascal Neuville, CEO of Domain Therapeutics, commented: “The nomination of our first-in-class PAR2 NAM drug candidate, DT-9045, is an exciting step forward for Domain Therapeutics and for cancer treatment in general.

ACCED, The Medication Safety Robot that Has Dominated the French Market for Ten Years, Continues Its Record-Breaking Commercial Expansion

Retrieved on: 
Donnerstag, April 27, 2023
Medical Supplies, Biotechnology, Technology, Managed Care, Other Health, Health, Pharmaceutical, Robotics, Health Technology, Medical Devices, Hospitals, Bed, Public, RFID, Hospital, Centre hospitalier, Medicine, Centre hospitalier universitaire Sainte-Justine, National Association Medical Staff Services, Patient, Patient safety, Child, Psychiatry, News, Approximation error, Automation

It is intended to improve patient safety, reduce medication errors, and maximize operational efficiency while providing secure and dependable medication preparation and dispensing processes.

Key Points: 
  • It is intended to improve patient safety, reduce medication errors, and maximize operational efficiency while providing secure and dependable medication preparation and dispensing processes.
  • Furthermore, the solution includes a reporting and analytics platform that provides hospitals with data-driven insights to improve operational performance.
  • Our D3 ACCED mechatronic robot is designed specifically to ensure complete patient safety, operational effectiveness, and financial viability.
  • We are confident that both hospitals and their patients will benefit greatly from our solution. "

CuePath Selected to Include Automated Compliance Monitoring with Centre Hospitalier de l'Université de Montréal

Retrieved on: 
Mittwoch, März 22, 2023
Community nursing, Piaggio, Methamphetamine, Centre hospitalier, Clinical trial, Medicine, Public, Research, Pharmacy, Patient safety, Canadian Institutes of Health Research, Medical device

VANCOUVER, BC, March 22, 2023 /PRNewswire/ - CuePath Innovation, a provider of medication adherence solutions for the home healthcare market, announced today that it has been selected to provide its medication compliance monitoring system for a clinical trial led by the Centre Hospitalier de l'Université de Montréal Research Centre (CRCHUM).

Key Points: 
  • VANCOUVER, BC, March 22, 2023 /PRNewswire/ - CuePath Innovation, a provider of medication adherence solutions for the home healthcare market, announced today that it has been selected to provide its medication compliance monitoring system for a clinical trial led by the Centre Hospitalier de l'Université de Montréal Research Centre (CRCHUM).
  • This will be the first clinical trial in Canada to use Cuepath for automated medication compliance monitoring in the research protocol.
  • CuePath brings its automated medication compliance monitoring and analysis to the clinical trial, so researchers can accurately monitor and collect detailed data on medication intake, enhancing patient safety and allowing better evidence overall for treatment adherence.
  • CuePath CEO, Ken Piaggio, stated, "This will be the first clinical trial in Canada to use CuePath's automated medication adherence monitoring."

AP-HP signs 4-year agreement with Proactis and Cegedim to optimise the management of its supply

Retrieved on: 
Mittwoch, März 1, 2023
AP-HP, B2B, Centre hospitalier, Heart, Hospital, Finance, AP, Patient, Retail, News, Cegedim

A Parisian university hospital with a European dimension and a worldwide reputation, the AP-HP welcomes 10 million patients every year.

Key Points: 
  • A Parisian university hospital with a European dimension and a worldwide reputation, the AP-HP welcomes 10 million patients every year.
  • It is the largest employer in the Ile de France region, with more than 100,000 employees in its 39 establishments.
  • Olivier Jung, Director of Proactis France, added: "Proactis is proud that the AP-HP has renewed its confidence in the use of our marketplace and its platform for the dematerialisation of orders.
  • This project is at the heart of the performance challenges facing the AP-HP's Finance department.

AP-HP signs 4-year agreement with Proactis and Cegedim to optimise the management of its supply

Retrieved on: 
Mittwoch, März 1, 2023
AP-HP, B2B, Centre hospitalier, Heart, Hospital, Finance, AP, Patient, Retail, News, Cegedim

A Parisian university hospital with a European dimension and a worldwide reputation, the AP-HP welcomes 10 million patients every year.

Key Points: 
  • A Parisian university hospital with a European dimension and a worldwide reputation, the AP-HP welcomes 10 million patients every year.
  • It is the largest employer in the Ile de France region, with more than 100,000 employees in its 39 establishments.
  • Olivier Jung, Director of Proactis France, added: "Proactis is proud that the AP-HP has renewed its confidence in the use of our marketplace and its platform for the dematerialisation of orders.
  • This project is at the heart of the performance challenges facing the AP-HP's Finance department.

Deenova Pursues Its Unstoppable Growth on the French Market with 6 New Contract Awards

Retrieved on: 
Montag, Januar 16, 2023
Technology, Medical Devices, Hospitals, Health Technology, Health, Electronic Design Automation, Robotics, Pharmaceutical, IOT (Internet of Things), Mont Blanc, National Association Medical Staff Services, RFID, Patient safety, Foot, Heart, Sallanches, Etablissement Notre-Dame-de-la-Compassion, Bed, Gorze, Haute-Savoie, Grand Est, Psychiatry, Territoire de Belfort, Centre hospitalier, Automation, Aube, Surgery, Airline, Hospital, Geriatrics

Deenova confirms its undisputed leadership on the French Hospital Pharmacy Automation market by announcing six new contract awards in France of 10 market leading D3 ACCED mechatronic solutions through the previous victory at competitive UNIHA tender.

Key Points: 
  • Deenova confirms its undisputed leadership on the French Hospital Pharmacy Automation market by announcing six new contract awards in France of 10 market leading D3 ACCED mechatronic solutions through the previous victory at competitive UNIHA tender.
  • Loïc Bessin , Managing Director of Deenova France, proudly stated: “This is the best way to start 2023, and confirms our undisputed leadership in France.
  • More than 50 healthcare institutions have chosen our robots, because of their reliability, speed and ease of use.
  • Gorze is a commune of the Grand Est Region in north-eastern France and the Etablissement public départemental de santé has 310 beds.

Domain Therapeutics strengthens Scientific Advisory Board with appointment of immuno-oncology experts

Retrieved on: 
Donnerstag, Dezember 8, 2022
University of Nice Sophia Antipolis, Coronavirus Scientific Advisory Board (Turkey), Sarcoma, GPCR, Neoplasm, Entrepreneurship, Faculty of Pharmacy, University of Lisbon, SAB, Cancer, Memorial Sloan Kettering Cancer Center, Principal investigator, Principal, Doctor of Philosophy, CHUM, MD, CD73, III, Immunosuppression, Metastasis, Centre hospitalier, Therapy, Faculty, University, Patient, Clockmaker, Pharmaceutical industry, Medicine, IO, Pharmacy

He is also involved in clinical and translational research in the field of rare tumors and sarcomas.

Key Points: 
  • He is also involved in clinical and translational research in the field of rare tumors and sarcomas.
  • Professor Italiano graduated from the University of Nice, France, and completed a post-doctoral fellowship at Memorial Sloan Kettering Cancer Center, New York, US.
  • Co-Founder and Scientific Advisor of Surface Oncology and previously Scientific Advisor of Tarus Therapeutics, Professor Stagg is an internationally recognized expert working on identifying the mechanisms of immunosuppression.
  • Michel Bouvier, Chairman of Domain Therapeutics’ Scientific Advisory Board, commented: “As Domain moves towards the clinical phase to deliver differentiated GPCR-targeting immunotherapies for the precise treatment of cancer, it is great to see the strengthening of the Company’s Scientific Advisory Board with the addition of two highly distinguished scientists.

Novadip Biosciences SA Announces Positive Results from Phase 1/2 Clinical Trial in Patients with Severe Bone Non-Union of the Lower Limb Following Trauma

Retrieved on: 
Donnerstag, Dezember 8, 2022
Science, Biotechnology, Research, Pharmaceutical, Physical Therapy, Surgery, Health, Clinical Trials, Trauma, Injury, Ossification, CT, Human skeleton, IND, BNU, Doctor of Philosophy, DBM, MicroRNA, Patient, Tibia, Cancer, Extracellular matrix, How I Braved Anu Aunty and Co-Founded a Million Dollar Company, Mont-Saint-Guibert, Orthopedic surgery, Centre Hospitalier de Luxembourg, Ceramic, FDA, Pain, Diabetes, CPT, Obesity, Quality of life, US Foods, Physiology, Palpation, Smoking, Trial of the century, Safety, Nonunion, Centre hospitalier, Spinal fusion, OTE, Regeneration, Luxembourg, JAMA Surgery, Rush University Medical Center, Risk, Pharmaceutical industry, Medical imaging, Dentistry, Fracture, MD, EU

Highlights from the clinical study results include:

Key Points: 
  • Highlights from the clinical study results include:
    The results demonstrate NVD-003s ability to reverse severe bone deterioration and to achieve accelerated ossification.
  • A total of eight patients (89%) presented clinical healing during the two years of follow-up post-GS.
  • All patients achieved total weight bearing at six months and seven patients (78%) were walking normally at 2 years.
  • The studys primary endpoint was safety of NVD003 in adult patients with recalcitrant lower limb non-union.